|
Treatment of lower-risk myelodysplastic syndromes |
Oct 2024 |
Haematologica |
Myelodysplastic Syndromes (MDS) |
|
Treatment of lower-risk myelodysplastic syndromes |
Feb 2025 |
Haematologica |
Myelodysplastic Syndromes (MDS) |
|
Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities |
Apr 2024 |
Current Hematologic Malignancy Reports |
Myelodysplastic Syndromes (MDS) |
|
Treatment of newly diagnosed severe aplastic anemia in children: Evidence-based recommendations |
May 2024 |
Pediatric Blood & Cancer |
Aplastic Anemia |
|
Treatment of newly diagnosed severe aplastic anemia in children: Evidence-based recommendations |
Aug 2024 |
Pediatric Blood Cancer |
Aplastic Anemia, Pediatric |
|
Treatment of relapsed/refractory severe aplastic anemia in children: Evidence-based recommendations |
Aug 2024 |
Pediatric Blood Cancer |
Aplastic Anemia |
|
Treatment options for lower-risk myelodysplastic syndromes. Where are we now? |
Jan 2021 |
Therapeutic Advances in Hematology |
Myelodysplastic Syndromes (MDS) |
|
Treatment sequence of lenalidomide and hypomethylating agents and the impact on clinical outcomes for patients with myelodysplastic syndromes. |
Jan 2019 |
Leuk Lymphoma. |
Myelodysplastic Syndromes (MDS) |
|
Understanding pharmacological complement inhibition in paroxysmal nocturnal hemoglobinuria |
Mar 2024 |
Haematologica |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Use of Immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis |
Apr 2019 |
Haemotologica |
Myelodysplastic Syndromes (MDS) |
